The University of Queensland, School of Human Movement Studies, Blair Drive, St Lucia Campus, Brisbane, Queensland 4072, Australia.
Arthritis Res Ther. 2010;12(1):R25. doi: 10.1186/ar2932. Epub 2010 Feb 12.
Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.
Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine differences in outcome measures between assessments.
During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements were seen between Weeks 6 and 12. No significant differences were found between walking groups.
In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger sample is needed to support these preliminary findings.
Australian Clinical Trials Registry ACTRN012607000159459.
骨关节炎(OA)的治疗包括非药物和药物治疗。尽管步行通常被推荐用于减轻 OA 患者的疼痛和增加身体功能,但硫酸氨基葡萄糖也已被用于缓解疼痛和减缓 OA 的进展。本研究评估了渐进式步行计划和硫酸氨基葡萄糖摄入对轻至中度髋或膝 OA 患者 OA 症状和身体活动参与度的影响。
36 名低活动参与者(年龄 42 至 73 岁)每天服用 1500 毫克硫酸氨基葡萄糖 6 周,之后开始为期 12 周的渐进式步行计划,同时继续服用氨基葡萄糖。他们被随机分配到每周步行 3 天或 5 天,并使用计步器监测步数。对于两组,步行水平在最初的 6 周内逐渐增加到每天 3000 步,接下来的 6 周增加到每天 6000 步。主要结果包括身体活动水平、身体功能(自我调节步速测试)和 WOMAC 骨关节炎指数的疼痛、僵硬和身体功能。评估在基线以及 6、12、18 和 24 周随访时进行。Mann-Whitney 检验用于检验每个评估时组间的结果测量差异,Wilcoxon 符号秩检验用于检验评估之间的结果测量差异。
在研究的前 6 周(仅补充氨基葡萄糖),身体活动水平、身体功能和总 WOMAC 评分均有所改善(P<0.05)。从步行计划开始(第 6 周)到最后一次随访(第 24 周),这些结果进一步改善(P<0.05),尽管大多数改善发生在第 6 至 12 周之间。步行组之间没有发现显著差异。
对于髋或膝 OA 患者,至少每周 3 天,每天至少行走 3000 步(约 30 分钟),同时服用硫酸氨基葡萄糖,可能会减轻 OA 症状。需要一项更大规模的样本量更充足的研究来支持这些初步发现。
澳大利亚临床试验注册处 ACTRN012607000159459。